{"id":"W2165181124","doi":"10.1200/jco.2007.12.5807","title":"Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":169,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"McGill University; Pfizer Pharmaceuticals; American Society of Clinical Oncology; Pfizer","keywords":"Medicine; Taxane; Chemotherapy; Internal medicine; Neutropenia; Clinical endpoint; Lung cancer; Oncology; Phases of clinical research; Gastroenterology; Surgery; Cancer; Urology; Breast cancer; Randomized controlled trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001394354,0.001663986,0.002736247,0.0003822063,0.0003749979,0.0008562543,0.000883678,0.001570601,0.005517002],"category_scores_gemma":[0.0011969,0.0007926102,0.001133323,0.0003269902,0.001361447,0.0008308601,0.0003427591,0.002804993,0.0009846156],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008822528,"about_ca_system_score_gemma":0.001536418,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005278026,"about_ca_topic_score_gemma":0.001582717,"domain_scores_codex":[0.999534,0.00026872,0.00002507455,0.00007005822,0.00003702104,0.00006512718],"domain_scores_gemma":[0.9991606,0.0001864141,0.0001840544,0.0000748485,0.00005141874,0.0003426799],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9556357,0.01672577,0.0005094356,0.0003693512,0.0004134576,0.00005185127,0.0000415457,0.0008245352,0.008995893,0.0001071317,0.0007815742,0.01554391],"study_design_scores_gemma":[0.8729274,0.1239559,0.0008158262,0.00001289108,0.0001492311,0.00004146655,0.00001122326,0.0004725217,0.001012474,0.0000816621,0.0005085678,0.00001087549],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910628,0.001257437,0.0005570128,0.0005094215,0.0006859245,0.003889882,0.0006899032,0.0001007913,0.001246922],"genre_scores_gemma":[0.9862532,0.001276185,0.002023646,0.0008861535,0.0004942862,0.00419037,0.001099662,0.00002027426,0.003756243],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005517002,"threshold_uncertainty_score":0.01845622,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0432886893044225,"score_gpt":0.382074831658081,"score_spread":0.3387861423536585,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}